RGS5 Gene can Reverse Angiogenesis

Written by on April 17, 2008 in in the news, research, What Causes Rosacea? with 1 Comment

From: Aussies stop cancer tumour frenzy

Researchers based at the Western Australian Institute for Medical Research have discovered a gene that can reverse angiogenesis – the growth of blood vessels inside a tumour.

Their work, led by associate Professor Ruth Ganss, is a world first and has been recognised by internationally-renowned scientific journal Nature in its weekly edition, published online today.

Professor Ganss described the gene, named RGS5, as a “master gene” which, when removed, can trigger a process capable of destroying cancerous tumours.

Also from New technique reverses growth of cancer blood vessels

Reversing abnormal vessel growth represents a fresh approach to tackling angiogenesis, with most current research focusing on how to block or kill tumour-feeding blood vessels.

She adds: “By understanding what is actually going on in the tumour itself, the ultimate hope is that we’ll be able to work on making current therapeutic approaches even more successful and reducing side effects of them.”

Even though this research relates to blood vessel growth in cancerous tumours, it could also be interesting for rosacea researchers looking for how angiogenesis is involved with development of rosacea.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

1 Reader Comment

  1. yumecouk says:

    This is obviously a great discovery but it makes me wonder if we rosaceans are more at a risk for cancer because we share this blood vessel growth problem..i certainly hope there is no link but i couldn’t help but wonder…

Leave your comment here


Discover more from Rosacea Support Group

Subscribe now to keep reading and get access to the full archive.

Continue reading

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.